$TEVA

Zaks Tal Zvi sold $593 of TEVA

Zaks Tal Zvi sold 17 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.87 on 2026-08-05.

Original reporting
SEC EDGAR · Zaks Tal Zvi
Published Aug 10, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (17 shares at $34.8655, $592.71 total) and post-transaction holdings (73,247 shares).

02

Market read

Traders may note the insider sale for sentiment, but the disclosed transaction size is too small to be a standalone fundamental catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing provides no rationale or follow-on buying.

Relevance 3/10Novelty 5/10Timing: filed 2026-08-10, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for TEVA, reported via SEC EDGAR.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

SEC Form 4 shows director Zaks Tal Zvi sold 17 shares of TEVA at $34.8655 on 2026-08-05, totaling $592.71.

Expected impact

Low likelihood of a sustained price move; any reaction would likely be brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size ($592.71) is small relative to a large public issuer, and there is no accompanying corporate event or guidance change in the text.

Market effects

No sector read-through is provided; this is company-specific insider selling only.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a disclosed 10b5-1 plan, some traders may interpret it as a signal, even if the dollar amount is small.

Key entities

  • TEVA

    Teva Pharmaceutical Industries Ltd, the subject of the insider transaction filing.

  • Zaks Tal Zvi

    Director who sold 17 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.